Susquehanna International Group
ENTA icon

Susquehanna International Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Susquehanna International Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,100
Closed -$396K – 12648
2025
Q3 		$396K Buy
+33,100
New +$265K ﹤0.01% 9498
2023
Q2 		– Sell
-8,300
Closed -$336K – 12325
2023
Q1 		$336K Buy
+8,300
New +$396K ﹤0.01% 9476
2022
Q4 		– Sell
-5,500
Closed -$285K – 12721
2022
Q3 		$285K Sell
5,500
-6,600
-55% -$386K ﹤0.01% 9923
2022
Q2 		$572K Buy
12,100
+8,800
+267% +$478K ﹤0.01% 7924
2022
Q1 		$235K Sell
3,300
-1,600
-33% -$104K ﹤0.01% 10850
2021
Q4 		$366K Buy
+4,900
New +$385K ﹤0.01% 10002
2021
Q3 		– Sell
-17,100
Closed -$753K – 12902
2021
Q2 		$753K Sell
17,100
-23,900
-58% -$1.17M ﹤0.01% 8551
2021
Q1 		$2.02M Sell
41,000
-3,100
-7% -$155K ﹤0.01% 5890
2020
Q4 		$1.86M Buy
44,100
+32,100
+268% +$1.41M ﹤0.01% 5253
2020
Q3 		$549K Buy
+12,000
New +$581K ﹤0.01% 7475
2020
Q2 		– Sell
-11,200
Closed -$576K – 10289
2020
Q1 		$576K Sell
11,200
-20,800
-65% -$1.11M ﹤0.01% 6608
2019
Q4 		$1.98M Sell
32,000
-45,100
-58% -$2.8M ﹤0.01% 4358
2019
Q3 		$4.63M Sell
77,100
-13,900
-15% -$1.03M ﹤0.01% 2840
2019
Q2 		$7.68M Buy
91,000
+52,700
+138% +$4.74M ﹤0.01% 2182
2019
Q1 		$3.66M Buy
38,300
+1,900
+5% +$170K ﹤0.01% 2861
2018
Q4 		$2.58M Buy
36,400
+31,200
+600% +$2.39M ﹤0.01% 3140
2018
Q3 		$444K Sell
5,200
-7,900
-60% -$791K ﹤0.01% 6759
2018
Q2 		$1.52M Buy
13,100
+8,200
+167% +$818K ﹤0.01% 4515
2018
Q1 		$396K Buy
+4,900
New +$377K ﹤0.01% 7103
2017
Q4 		– Sell
-9,100
Closed -$426K – 9385
2017
Q3 		$426K Sell
9,100
-11,800
-56% -$474K ﹤0.01% 6787
2017
Q2 		$752K Sell
20,900
-19,700
-49% -$630K ﹤0.01% 5865
2017
Q1 		$1.25M Buy
+40,600
New +$1.26M ﹤0.01% 4662
2016
Q4 		– Sell
-8,300
Closed -$221K – 9691
2016
Q3 		$221K Sell
8,300
-18,000
-68% -$418K ﹤0.01% 7421
2016
Q2 		$580K Sell
26,300
-41,400
-61% -$1.08M ﹤0.01% 5873
2016
Q1 		$1.99M Sell
67,700
-82,400
-55% -$2.29M ﹤0.01% 3778
2015
Q4 		$4.96M Buy
150,100
+129,800
+639% +$4.23M ﹤0.01% 2554
2015
Q3 		$734K Sell
20,300
-8,100
-29% -$348K ﹤0.01% 6359
2015
Q2 		$1.28M Sell
28,400
-9,200
-24% -$358K ﹤0.01% 5671
2015
Q1 		$1.15M Sell
37,600
-20,800
-36% -$809K ﹤0.01% 5457
2014
Q4 		$2.97M Buy
58,400
+17,800
+44% +$797K ﹤0.01% 3753
2014
Q3 		$1.61M Buy
40,600
+13,700
+51% +$546K ﹤0.01% 5015
2014
Q2 		$1.16M Buy
+26,900
New +$1.03M ﹤0.01% 5741

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna International Group's ENTA Position: Q1 2026 in Review

Susquehanna International Group increased its Enanta Pharmaceuticals (ENTA) stake by 36% in Q1 2026, buying an estimated $50.1K and bringing the position to 14,208 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #11807.

Susquehanna International Group first reported a position in ENTA in Q1 2014 and has held it in 36 quarters since. The position peaked at $5.62M in Q2 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Susquehanna International Group held 14,208 shares of Enanta Pharmaceuticals worth $179K as of Q1 2026.
  • Susquehanna International Group bought 3,741 Enanta Pharmaceuticals shares in Q1 2026, an estimated $50.1K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11807 holding.
  • Susquehanna International Group first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 36 quarters since.
  • Susquehanna International Group's Enanta Pharmaceuticals position peaked at $5.62M in Q2 2019.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.